Maraviroc 150mg T
| Product Overview | |
| Generic Name | Maraviroc 150mg T |
| Brand Name(s) | Selzentry (U.S.), Celsentri (EU/other), Axentri (India) |
| Form | Film-coated tablets |
| Strength | 150mg |
| Therapeutic Class | CCR5 receptor antagonist |
| ATC Code | J05AX09 |
| Manufacturing & Regulatory | |
| Manufacturer | Emcure Pharmaceuticals Ltd |
| Country | India |
| GMP Compliance | WHO-GMP recognition; Emcure appears in MHRA’s GMP |
| DMF/CEP | exist for Maraviroc API (Type II) |
| COFEPRIS | 010.000.5324.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 100 pcs |
| Shelf Life | 24 months on export packs |
| Storage | store at/below 30 °C |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| SDS | Upon Request, not publicly posted |
| CTD Summary | CTD from originator; generic use abbreviated formats |
Description
Maraviroc is a CCR5 antagonist used in combination with other antiretrovirals for CCR5-tropic HIV-1 infection in adults and pediatric patients (≥2 years, per label). CCR5 tropism testing is required prior to initiation; it is not recommended in patients with CXCR4 or dual/mixed-tropic HIV-1.
